Your browser is no longer supported. Please, upgrade your browser.
Settings
GLYC GlycoMimetics, Inc. daily Stock Chart
GLYC [NASD]
GlycoMimetics, Inc.
Index- P/E- EPS (ttm)-1.45 Insider Own0.80% Shs Outstand31.14M Perf Week4.74%
Market Cap358.11M Forward P/E- EPS next Y-0.81 Insider Trans-1.58% Shs Float30.23M Perf Month-5.19%
Income-32.20M PEG- EPS next Q-0.37 Inst Own64.20% Short Float13.45% Perf Quarter154.99%
Sales0.02M P/S19357.30 EPS this Y-122.80% Inst Trans0.94% Short Ratio1.52 Perf Half Y100.70%
Book/sh1.36 P/B8.46 EPS next Y42.60% ROA-70.20% Target Price14.25 Perf Year42.33%
Cash/sh1.11 P/C10.35 EPS next 5Y- ROE-81.60% 52W Range3.82 - 16.94 Perf YTD88.52%
Dividend- P/FCF- EPS past 5Y21.80% ROI- 52W High-32.11% Beta3.21
Dividend %- Quick Ratio7.80 Sales past 5Y- Gross Margin- 52W Low201.05% ATR0.72
Employees42 Current Ratio7.80 Sales Q/Q- Oper. Margin- RSI (14)48.72 Volatility5.48% 6.59%
OptionableYes Debt/Eq0.00 EPS Q/Q14.70% Profit Margin- Rel Volume0.08 Prev Close11.83
ShortableYes LT Debt/Eq0.00 EarningsAug 07 Payout- Avg Volume2.67M Price11.50
Recom1.40 SMA200.83% SMA504.47% SMA20060.64% Volume200,440 Change-2.79%
Jul-26-16Initiated SunTrust Buy
Mar-17-15Reiterated Stifel Buy $13 → $14
Jul-19-17 08:23AM  GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : July 19, 2017 Capital Cube
Jul-06-17 09:00AM  GlycoMimetics to Receive European Patent for GMI-1271 Business Wire
Jun-30-17 09:00AM  Are Options Traders Betting on a Big Move in GlycoMimetics (GLYC) Stock? Zacks
Jun-12-17 09:00AM  GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors Business Wire
Jun-07-17 08:00AM  Today's Research Reports on Top Tech Stocks: GlycoMimetics and Acorda Therapeutics Accesswire -6.18%
Jun-05-17 04:00PM  GlycoMimetics to Present at Jefferies 2017 Global Healthcare Conference Business Wire -14.47%
12:47PM  Why GlycoMimetics Is Tumbling 13.4% Today Motley Fool
07:00AM  GlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting Business Wire
May-31-17 09:00AM  GlycoMimetics Completes Enrollment of Relapsed/Refractory AML Patient Cohort in Phase 2 Portion of Clinical Trial of GMI-1271 Business Wire -5.44%
May-30-17 04:00PM  GlycoMimetics Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
May-25-17 04:01PM  Here's Why GlycoMimetics Rose as Much as 21% Today Motley Fool
09:25AM  GlycoMimetics GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia Business Wire
May-24-17 08:00AM  GlycoMimetics Announces Pricing of Public Offering of Common Stock Business Wire +5.66%
May-23-17 11:11AM  Shark Bites: There Wasn't Even a Dip to Buy TheStreet.com +20.35%
May-22-17 04:01PM  GlycoMimetics Announces Proposed Public Offering of Common Stock Business Wire -13.71%
08:00AM  Today's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and GlycoMimetics Accesswire
May-19-17 01:55PM  ETFs with exposure to GlycoMimetics, Inc. : May 19, 2017 Capital Cube +19.59%
01:28PM  Why GlycoMimetics Is Ripping 19% Higher Today Motley Fool
08:35AM  GlycoMimetics (GLYC) Shows Strength: Stock Jumps 98.7% Zacks
08:00AM  Today's Research Reports on Stocks to Watch: GlycoMimetics and Endologix Accesswire
May-18-17 03:15PM  Here's Why GlycoMimetics (GLYC) Stock Skyrocketed Over 100% Today Zacks +98.70%
10:57AM  Don't Trust the Bounce Yet TheStreet.com
06:30AM  GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML Business Wire
May-17-17 04:10PM  GlycoMimetics GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia Business Wire
May-08-17 09:04AM  GlycoMimetics reports 1Q loss Associated Press
09:00AM  GlycoMimetics Reports Program Updates and First Quarter 2017 Results Business Wire
May-02-17 09:00AM  GlycoMimetics Announces Publication of Preclinical Data Showing Role of E-selectin Ligands in Multiple Myeloma Business Wire
Apr-20-17 10:44AM  GlycoMimetics to Present New AML Clinical Data at ASCO 2017 Annual Meeting Business Wire
Apr-05-17 04:49PM  ETFs with exposure to GlycoMimetics, Inc. : April 5, 2017 Capital Cube
Mar-15-17 02:00PM  GlycoMimetics, Inc. :GLYC-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Capital Cube
Mar-13-17 04:01PM  GLYCOMIMETICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
09:30AM  GlycoMimetics Appoints Scott Koenig of MacroGenics to Board of Directors Business Wire
Mar-07-17 01:04PM  GLYCOMIMETICS INC Financials
09:00AM  GlycoMimetics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271 Business Wire
Mar-01-17 08:52PM  GlycoMimetics to Present New Preclinical Data in Multiple Myeloma at AACR Annual Meeting 2017 Business Wire
09:54AM  GlycoMimetics reports 4Q loss Associated Press
09:46AM  GLYCOMIMETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit
09:33AM  GLYCOMIMETICS INC Files SEC form 10-K, Annual Report
09:30AM  GlycoMimetics Reports Fourth Quarter and Year-End 2016 Results Business Wire
Feb-28-17 04:00PM  GlycoMimetics to Present at Cowen 37th Annual Health Care Conference Business Wire
Jan-12-17 02:45PM  Pharma company executives debate drug pricing increases Reuters
Dec-16-16 12:24AM  How Dawson Geophysical Company (DWSN) Stacks Up Against Its Peers Insider Monkey
Dec-05-16 10:01AM  GlycoMimetics' GMI-1271 Continues to Yield High Remission Rates, Favorable Tolerability in Two Phase 2 Arms of Ongoing Phase 1/2 Clinical Trial for AML Business Wire
Nov-22-16 08:59AM  Novartis Buys Selexys on Favorable Phase II Data on SelG1
Nov-10-16 09:00AM  GlycoMimetics to Present at Upcoming Healthcare Investor Conferences Business Wire
Nov-08-16 09:00AM  GlycoMimetics to Present Preclinical Cancer Results at Society for Immunotherapy of Cancer Meeting Business Wire
Nov-04-16 09:46AM  GLYCOMIMETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit
09:20AM  GlycoMimetics reports 3Q loss
09:15AM  GlycoMimetics Reports Third Quarter 2016 Results and Progress in Clinical Development Business Wire
09:03AM  GLYCOMIMETICS INC Files SEC form 10-Q, Quarterly Report
Nov-03-16 09:32AM  Data from Three GlycoMimetics Drug Candidates to Be Highlighted at 58th Annual American Society of Hematology (ASH) Meeting Business Wire
Sep-23-16 09:31AM  GLYCOMIMETICS INC Files SEC form 8-K, Change in Directors or Principal Officers
Sep-14-16 09:15AM  GlycoMimetics Doses First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple Myeloma Business Wire
Sep-06-16 09:15AM  GlycoMimetics Initiates Dosing in Phase 1 Clinical Trial of GMI-1359 Business Wire
Aug-16-16 09:15AM  GlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces Inflammatory Responses After Heart Attack Business Wire
Aug-15-16 12:01PM  GlycoMimetics Initiated At Outperform By Cowen And Company
Aug-09-16 11:05AM  3 Biotech Stocks With Catalysts That Have 90% to 500% Upside Potential at 24/7 Wall St.
Aug-08-16 09:15AM  GlycoMimetics to Present at Canaccord Genuity 36th Annual Growth Conference Business Wire -6.66%
Aug-05-16 09:30AM  Zacks.com featured highlights: GlycoMimetics, Lion Biotechnologies, AMN Healthcare Services, Gibraltar Industries and Coherent
Aug-04-16 07:27PM  GlycoMimetics reports 2Q loss
04:33PM  GLYCOMIMETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit
04:15PM  GlycoMimetics Reports Second Quarter 2016 Results Business Wire
04:03PM  GLYCOMIMETICS INC Files SEC form 10-Q, Quarterly Report
Jul-29-16 04:01PM  Cardinal Health (CAH) Q4 Earnings: Disappointment in Store?
Jul-26-16 07:34AM  Coverage initiated on GlycoMimetics by SunTrust
Jun-28-16 09:00AM  GlycoMimetics Doses First Patient in Phase 2 Portion of Clinical Trial of GMI-1271 in Newly Diagnosed Acute Myeloid Leukemia Business Wire
Jun-24-16 08:00AM  GlycoMimetics (GLYC) Worth Watching: Stock Surges 13.1%
Jun-17-16 04:13PM  GLYCOMIMETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements -16.69%
09:00AM  GlycoMimetics Announces Pricing of Public Offering of Common Stock Business Wire
Jun-16-16 04:01PM  GlycoMimetics Announces Proposed Public Offering of Common Stock Business Wire
Jun-13-16 09:00AM  GlycoMimetics GMI-1271 Receives FDA Fast Track Designation for Treatment of Acute Myeloid Leukemia Business Wire -7.41%
Jun-10-16 06:11AM  GLYCOMIMETICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
06:00AM  GlycoMimetics GMI-1271 Yields High Remission Rates and Favorable Tolerability in Phase 1 Portion of Phase 1/2 Clinical Trial for AML Business Wire
Jun-06-16 09:00AM  GlycoMimetics Doses First Patient in Phase 2 Portion of GMI-1271 Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia Business Wire -10.48%
Jun-02-16 05:27PM  GLYCOMIMETICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:00AM  GlycoMimetics to Present at Jefferies 2016 Healthcare Conference Business Wire
May-26-16 09:39AM  Will GlycoMimetics (GLYC) Continue to Surge Higher?
May-25-16 06:44PM  The 3 Best Developmental Stage Biotech Stocks Surging Now
02:00PM  GlycoMimetics Announces Publication of New Preclinical Data with GMI-1271 in Science Translational Medicine Business Wire
May-19-16 09:30AM  Initial Efficacy Data for GlycoMimetics GMI-1271 Combined with Chemotherapy in Patients with AML to Be Presented at European Hematology Association 21st Congress Business Wire +8.31%
May-18-16 03:37PM  GLYCOMIMETICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-04-16 09:43AM  GLYCOMIMETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit
09:37AM  GLYCOMIMETICS INC Files SEC form 10-Q, Quarterly Report
09:06AM  GlycoMimetics reports 1Q loss
09:00AM  GlycoMimetics Reports First Quarter 2016 Results Business Wire
Apr-25-16 04:30PM  GlycoMimetics Data on GMI-1271 Treatment of Acetaminophen-Triggered Liver Toxicity to Be Presented at Digestive Disease Week Conference Business Wire
Mar-29-16 04:26PM  GLYCOMIMETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Mar-21-16 10:19AM  GLYCOMIMETICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
09:41AM  GlycoMimetics Appoints ImmunoGen CEO Daniel Junius to Board of Directors at noodls
09:30AM  GlycoMimetics Appoints ImmunoGen CEO Daniel Junius to Board of Directors Business Wire
Mar-17-16 09:30AM  GlycoMimetics to Present New Preclinical Data on Its E-selectin-CXCR4 Dual Antagonist at AACR Annual Meeting 2016 Business Wire
Mar-10-16 11:17AM  GlycoMimetics, Inc. :GLYC-US: Earnings Analysis: 2015 By the Numbers -5.21%
Mar-02-16 08:30AM  GlycoMimetics Announces Initial Clinical Data from Phase 1 Portion of Clinical Trial of GMI-1271 in AML Patients Business Wire
Mar-01-16 04:36PM  GLYCOMIMETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
09:30AM  GlycoMimetics to Present at Cowen and Companys 36th Annual Health Care Conference Business Wire
Feb-29-16 07:51PM  GLYCOMIMETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit
06:17PM  GlycoMimetics reports 4Q loss
05:00PM  GlycoMimetics Reports Fourth Quarter and Year-End 2015 Results Business Wire
Feb-01-16 04:33PM  GlycoMimetics to Present at 18th Annual BIO CEO & Investor Conference at noodls
04:00PM  GlycoMimetics to Present at 18th Annual BIO CEO & Investor Conference Business Wire
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thackray Helen M.SVP Clinical Development, CMOMay 25Sale15.572,00031,140152,615May 30 04:07 PM
Thackray Helen M.SVP Clinical Development, CMOMay 19Sale12.142,00024,280154,615May 22 09:23 PM
Magnani John L.SVP of Research, CSOMay 10Option Exercise1.128,9289,99999,302May 11 04:00 PM
JUNIUS DANIEL MDirectorDec 20Buy6.015,00030,0505,000Dec 21 04:23 PM
Thackray Helen M.VP Clinical Development, CMOOct 03Sale7.004,00028,001156,615Oct 04 04:22 PM